CJC-1295 (no DAC) vs GHRP-6
Both CJC-1295 (no DAC) and GHRP-6 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | GHRP-6 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — research compound |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 100–300 mcg, 1–3 times daily (subcutaneous) |
| Clinics Indexed | 156 | 64 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, appetite |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.